Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$20.68 - $39.85 $12,428 - $23,949
601 Added 1.74%
35,131 $751,000
Q1 2023

May 12, 2023

SELL
$38.82 - $54.59 $45,807 - $64,416
-1,180 Reduced 3.3%
34,530 $1.4 Million
Q3 2022

Nov 14, 2022

BUY
$48.29 - $71.27 $79,581 - $117,452
1,648 Added 4.84%
35,710 $1.85 Million
Q1 2022

May 13, 2022

SELL
$56.06 - $74.11 $144,634 - $191,203
-2,580 Reduced 7.04%
34,062 $2.43 Million
Q4 2021

Feb 14, 2022

BUY
$60.19 - $97.37 $16,853 - $27,263
280 Added 0.77%
36,642 $2.74 Million
Q3 2021

Nov 12, 2021

SELL
$41.02 - $58.65 $19,689 - $28,152
-480 Reduced 1.3%
36,362 $2.07 Million
Q1 2021

May 14, 2021

SELL
$41.69 - $54.95 $112,979 - $148,914
-2,710 Reduced 6.85%
36,842 $1.82 Million
Q3 2020

Nov 13, 2020

BUY
$43.36 - $53.53 $161,299 - $199,131
3,720 Added 10.38%
39,552 $1.81 Million
Q4 2019

Feb 14, 2020

SELL
$57.95 - $66.61 $283,955 - $326,389
-4,900 Reduced 12.03%
35,832 $2.21 Million
Q3 2019

Nov 14, 2019

BUY
$60.08 - $88.17 $334,765 - $491,283
5,572 Added 15.85%
40,732 $2.45 Million
Q2 2019

Aug 14, 2019

BUY
$81.3 - $97.35 $1.68 Million - $2.02 Million
20,700 Added 143.15%
35,160 $2.97 Million
Q1 2019

May 14, 2019

BUY
$69.08 - $105.66 $48,356 - $73,962
700 Added 5.09%
14,460 $1.38 Million
Q4 2018

Feb 14, 2019

BUY
$65.41 - $84.65 $189,689 - $245,485
2,900 Added 26.7%
13,760 $975,000
Q3 2018

Nov 14, 2018

BUY
$85.46 - $126.37 $130,326 - $192,714
1,525 Added 16.34%
10,860 $928,000
Q1 2018

May 10, 2018

BUY
$57.91 - $92.15 $28,955 - $46,075
500 Added 5.66%
9,335 $755,000
Q3 2017

Nov 14, 2017

BUY
$37.91 - $46.8 $334,934 - $413,478
8,835
8,835 $0

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $194M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Public Sector Pension Investment Board Portfolio

Follow Public Sector Pension Investment Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Public Sector Pension Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on Public Sector Pension Investment Board with notifications on news.